affno abstract
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma2017· article· en· Annals of Oncology· Biochemistry, Genetics and Molecular Biology
272
citations
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.